Dana-Farber’s John Quackenbush on how to fix our “messy data” problem
On day two of MedCity CONVERGE, John Quackenbush of the Dana-Farber Cancer Institute highlighted the benefits and the challenges that accompany big data.
On day two of MedCity CONVERGE, John Quackenbush of the Dana-Farber Cancer Institute highlighted the benefits and the challenges that accompany big data.
“Single mutations or single genomic alterations are only really getting us part of the way to a solution,” said John Quackenbush, director of the Center for Cancer Computational Biology and a keynote speaker at MedCity CONVERGE, on the state of precision medicine.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.